Stevens-Johnson syndrome, otherwise known as erythema multiforme majus, was first described in 1922 by Stevens and Johnson as a febrile illness with stomatitis, purulent conjunctivitis, and skin lesions. Case report: We report a 28-year-old married woman who presented with fever and was advised ciprofloxacin tablet. After taking two doses of the tablet, she developed papulo-vesicular rash involving the trunk and the upper and lower limbs, including mucous membranes. She also developed a painful red eye. She eventually developed jaundice and her case was ultimately diagnosed as ciprofloxacin-induced Stevens-Johnson syndrome. Discussion: Medications appear to be the most common cause of Stevens-Johnson syndrome. It commonly affects multiple organs. Treatment for Stevens-Johnson syndrome is as diverse as the symptoms and it should be begun by withdrawing any offending agent identified. Conclusion: Stevens-Johnson syndrome is a potentially fatal multiorgan disease. This aspect of the condition is best addressed by early involvement of medical specialists.
[1]. J. Wilkins L. Morrison C. R. White Jr. 1992 Oculocutaneous manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum Dermatol. Clin. 10 571–582.
[2]. T. P. Habif 1996 Clinical Dermatology 3rd edn Mosby-Year Book St Louis 570–572.
[3]. A. M. Stevens F. C. Johnson 1922 A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children Am. J. Dis. Child. 24 526–533.
[4]. H. Chan R. S. Stern K. A. Arndt et al.1990 The incidence of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis Arch. Dermatol. 126 43–47.
[5]. P. O. Fritsch R. Ruiz-Maldonado 1999 Stevens-Johnson syndrome toxic epidermal necrolysis I. M. Freedberg A. Z. Eisen K. Wolff et al.Fitzpatrick's Dermatology in General Medicine, vol. 1 5th edn McGraw-Hill New York 644–654.
[6]. J.-C. Roujeau J. P. Kelly L. Naldi et al.1995 Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis N. Engl. J. Med. 333 1600–1607.
[7]. T. Hazir M. Saleem K. A. Abbas 1997 Stevens-Johnson syndrome following measles vaccination J. Pak. Med. Assoc. 47 264–265.
[8]. Y. M. Tan K. L. Goh 1999 Esophageal stricture as a late complication of Stevens-Johnson syndrome Gastrointest. Endosc. 50 566–568.
[9]. W. J. Power M. Ghoraishi J. Merayo-Lloves et al.1995 Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum Ophthalmology 102 1669–1676.
[10]. J. C. Roujeau 1999 Treatment of severe drug eruptions J. Dermatol. 26 718–722.
[11]. J. A. Kazmierowski K. D. Wuepper 1988 Erythema multiforme T. T. Provost E. R. Farmer Current Therapy in Dermatology, vol. 2 BC Decker Philadelphia 47–48.
[12]. R. Patterson M. Miller M. Kaplan et al.1994 Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis Ann. Allergy 73 27–34.
[13]. R. Patterson L. C. Grammer P. A. Greenberger et al.1992 Stevens-Johnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS Allergy Proc. 13 89–95.
[14]. G. A. Noskin R. Patterson 1997 Outpatient management of Stevens-Johnson syndrome: a report of four cases and management strategy Allergy Asthma Proc. 18 29–32.